Revelation Biosciences is a life sciences company whose development of immunologic-based therapies is based on the well-established biology of phosphorylated hexaacyl disaccharide (PHAD) and its effect on the innate immune system. The company released 3Q2025 financials and showed good cash on hand. This will allow the company to advance previously announced test results for its Gemini product that were so good the Primary Investigator called them "shocking." This bodes well for the future of REVB as it looks toward commercialization.
